Teachers Retirement System of The State of Kentucky Has $4.39 Million Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Teachers Retirement System of The State of Kentucky lowered its position in shares of Omnicell, Inc. (NASDAQ:OMCLGet Rating) by 1.0% in the first quarter, Holdings Channel reports. The institutional investor owned 33,921 shares of the company’s stock after selling 327 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Omnicell were worth $4,392,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of OMCL. Covestor Ltd acquired a new position in Omnicell in the fourth quarter valued at about $29,000. Spire Wealth Management acquired a new position in Omnicell in the first quarter valued at about $25,000. Elequin Capital LP acquired a new position in Omnicell in the first quarter valued at about $30,000. Sageworth Trust Co raised its stake in Omnicell by 2,173.9% in the first quarter. Sageworth Trust Co now owns 1,046 shares of the company’s stock valued at $135,000 after purchasing an additional 1,000 shares in the last quarter. Finally, ARK Investment Management LLC raised its stake in Omnicell by 29.3% in the first quarter. ARK Investment Management LLC now owns 1,404 shares of the company’s stock valued at $182,000 after purchasing an additional 318 shares in the last quarter.

Omnicell Stock Performance

NASDAQ:OMCL opened at $95.27 on Monday. The stock has a market cap of $4.22 billion, a P/E ratio of 75.61, a price-to-earnings-growth ratio of 2.65 and a beta of 1.06. The company has a current ratio of 2.11, a quick ratio of 1.71 and a debt-to-equity ratio of 0.52. The stock’s 50-day moving average is $107.22 and its 200-day moving average is $115.00. Omnicell, Inc. has a 1-year low of $94.78 and a 1-year high of $187.29.

Omnicell (NASDAQ:OMCLGet Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported $0.84 earnings per share for the quarter, missing the consensus estimate of $0.85 by ($0.01). The firm had revenue of $331.39 million for the quarter, compared to the consensus estimate of $339.45 million. Omnicell had a return on equity of 10.37% and a net margin of 4.82%. The business’s revenue for the quarter was up 21.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.71 earnings per share. Equities research analysts anticipate that Omnicell, Inc. will post 2.7 earnings per share for the current year.

Insider Transactions at Omnicell

In other news, CEO Randall A. Lipps sold 13,000 shares of the business’s stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $111.04, for a total transaction of $1,443,520.00. Following the sale, the chief executive officer now directly owns 302,049 shares in the company, valued at $33,539,520.96. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Randall A. Lipps sold 13,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $111.04, for a total value of $1,443,520.00. Following the sale, the chief executive officer now directly owns 302,049 shares in the company, valued at $33,539,520.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Peter J. Kuipers sold 11,000 shares of the company’s stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $105.93, for a total value of $1,165,230.00. Following the completion of the sale, the chief financial officer now owns 61,326 shares in the company, valued at $6,496,263.18. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,500 shares of company stock worth $4,287,245. Insiders own 2.76% of the company’s stock.

Wall Street Analyst Weigh In

OMCL has been the subject of a number of analyst reports. SVB Leerink initiated coverage on Omnicell in a research note on Friday, July 15th. They issued a “market perform” rating and a $124.00 price target for the company. BTIG Research decreased their target price on Omnicell from $190.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, July 27th. Bank of America initiated coverage on Omnicell in a research report on Friday, September 9th. They issued a “buy” rating and a $120.00 target price on the stock. Piper Sandler decreased their target price on Omnicell from $162.00 to $150.00 and set an “overweight” rating on the stock in a research report on Monday, August 8th. Finally, KeyCorp initiated coverage on Omnicell in a research report on Thursday. They issued an “overweight” rating and a $130.00 target price on the stock. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $151.71.

About Omnicell

(Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

See Also

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCLGet Rating).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.